Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 10-Q

[x]

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

      For the quarterly period ended March 31, 2000

OR

[  ]

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

      or the transition period from ____________ to _____________

Commission file number   0-18443  

MEDICIS PHARMACEUTICAL CORPORATION

8125 North Hayden Road
  Scottsdale, AZ 85258-2463  
(Address of principal executive offices)

  (602) 808-8800  
(Registrant’s telephone number, including area code)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

YES   X   NO       

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Table of Contents

MEDICIS PHARMACEUTICAL CORPORATION

Table of Contents

2

Table of Contents

Part I. Financial Information

Item 1. Financial Statements

MEDICIS PHARMACEUTICAL CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

ASSETS

The accompanying notes are an integral part of this statement.

3

Table of Contents

MEDICIS PHARMACEUTICAL CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

LIABILITIES AND STOCKHOLDERS’ EQUITY

The accompanying notes are an integral part of this statement.

4

Table of Contents

MEDICIS PHARMACEUTICAL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

The accompanying notes are an integral part of this statement.

5

Table of Contents

MEDICIS PHARMACEUTICAL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

The accompanying notes are an integral part of this statement.

6

Table of Contents

MEDICIS PHARMACEUTICAL CORPORATION

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
March 31, 2000

1. ORGANIZATION AND BASIS OF PRESENTATION

Medicis Pharmaceutical Corporation and its wholly owned subsidiaries (“Medicis” or the “Company”) is the leading independent pharmaceutical company in the United States offering prescription products and an over-the-counter (“OTC”) product primarily for the treatment of dermatological conditions. The Company has built its business by successfully introducing new prescription products as well as acquiring rights to manufacture and sell certain dermatological products pursuant to several license and asset purchase agreements. The Company sells these products for use in various segments of the skin care market, including acne, acne-related conditions, fungal infections, psoriatic conditions, inflammatory skin conditions, pediculosis and pigmentation disorders. The Company derives a majority of its revenue from sales of the DYNACIN®, TRIAZ®, LOPROX® and LUSTRA® products (the “Key Products”).

The financial information is unaudited but reflects all adjustments, consisting only of normal recurring accruals, which are, in the opinion of the Company’s management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year. The financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto and Management’s Discussion and Analysis of Financial Condition and Results of Operations relating thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 1999 (“fiscal 1999”). Certain immaterial amounts on the face of the balance sheet have been reclassified to conform with the current period’s presentation.

2. COMPREHENSIVE INCOME

Total comprehensive income includes net income and other comprehensive income which consists of foreign currency translation adjustments and unrealized gains and losses on available-for-sale investments. Total comprehensive income for the three months ended March 31, 2000 (“the third quarter of fiscal 2000”) and the nine months ended March 31, 2000 was $11.1 million and $31.4 million, respectively. Total comprehensive income for the three months ended March 31, 1999 (“the third quarter of fiscal 1999”) and the nine months ended March 31, 1999 was $13.4 million and $24.9 million, respectively.

7

Table of Contents

3. SEGMENT INFORMATION

The Company adopted Statement of Financial Accounting Standards No. 131, “Disclosures about Segments of an Enterprise and Related Information” (“SFAS No. 131”). SFAS No. 131 established standards for reporting information regarding operating segments in annual financial statements and requires selected information to be presented in interim financial reports issued to shareholders. SFAS No. 131 also established standards for related disclosures about products and services, geographic areas and major customers. The adoption of SFAS No. 131 did not affect the Company’s consolidated financial position, results of operations or financial statement disclosures, as the Company operates only one business segment.

4. PURCHASE OF VECTRIN^® AND RELATED ASSETS

In September 1999, the Company purchased VECTRIN®, a branded minocycline HCl product line, and ownership of its abbreviated new drug application (“ANDA”) from Warner Chilcott, plc (“Warner Chilcott”). Under terms of the agreement, the Company paid Warner Chilcott $11.1 million cash at closing. Additionally, the Company is making royalty payments and may be obligated to make milestone payments conditioned upon the occurrence of certain events.

8

Table of Contents

5. EARNINGS PER SHARE

	The following table sets forth all computations of basic and diluted earnings per common share:

Options to purchase 2,199 and 102,327 shares of common stock at prices ranging from $45.69 to $49.50 and $35.50 to $49.50 per share were outstanding for the three and nine months ended March 31, 2000, respectively. These were not included in the computation of diluted earnings per share because the option exercise price was greater than the average market price of the Company’s common stock and, therefore, the effect would be anti-dilutive.

6. CONTINGENCIES

The Company and certain of its subsidiaries, from time to time, are parties to certain actions and proceedings incident to their business. Liability in the event of final adverse determinations in any of these matters is to the best of the Company’s belief based on estimates, either covered by insurance and/or established reserves or, in the opinion of management and after consultation with counsel, should not, in the aggregate, have a material adverse effect on the consolidated financial condition or results of operations of the Company and its subsidiaries.

9

Table of Contents

7. INVENTORIES

Although the Company utilizes third parties to manufacture and package inventories held for sale, the Company takes title to certain inventories and records the associated liability once inventories are manufactured. Inventories are valued at the lower of cost or market as determined by net realizable value using the first-in-first-out method. Inventories, net of reserves, at March 31, 2000 and June 30, 1999, consist of the following:

8. INCOME TAXES

Income taxes have been provided for using the liability method in accordance with Statement of Financial Accounting Standards No. 109, “Accounting for Income Taxes.” The provision for income taxes reflects management’s estimation of the effective tax rate expected to be applicable for the full fiscal year. This estimate is reevaluated by management each quarter based upon estimated tax expenses for the year.

At March 31, 2000, the Company took advantage of additional tax deductions available relating to the exercise of non-qualified stock options and disqualified dispositions of incentive stock options. Accordingly, the Company recorded a $5.7 million increase to equity with a corresponding $5.7 million reduction to taxes payable. Quarterly adjustments for the exercise of non-qualified stock options and disqualified dispositions of incentive stock options may vary as they relate to the actions of the option holder or shareholder.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

	The following discussion should be read in conjunction with the attached condensed consolidated financial statements and notes thereto and with the Company’s audited financial statements, notes to the consolidated financial statements and Management’s Discussion and Analysis of Financial Condition and Results of Operations relating thereto included or incorporated by reference in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 1999 (the “1999 Form 10-K”).
	This Quarterly Report on Form 10-Q (“Form 10-Q”) contains forward-looking statements that anticipate results based upon management’s plans that are subject to uncertainties. Forward-looking statements are based upon current expectations of future results. These statements may be identified by use of the words “expects,” “plans,” “anticipates,” “believes,” “estimates” and similar words used in conjunction with discussions of future operations or financial performance. The Company cannot ensure that any forward-looking statements will be accurate. Actual results could differ materially if underlying assumptions prove inaccurate or unknown risks or uncertainties develop. The Company assumes no

10

Table of Contents

	obligation to update forward-looking statements as a result of future events or developments.
	In Item 1 of the 1999 Form 10-K, as well as in this Form 10-Q, the Company discusses in more detail various factors that could cause actual results to vary from expectations. The Company notes these factors as permitted by the Private Securities Litigation Reform Act of 1995. Investors should understand that it is not possible to predict or identify all such factors and should not consider such factors to be a complete statement of all potential risks and uncertainties that may affect the Company’s business.

      Overview

	Medicis was founded in 1987 to develop and market prescription and over-the-counter (“OTC”) products to treat dermatological conditions. Innovative Therapeutics, Inc. (the predecessor of the Company) was incorporated under the laws of the District of Columbia on July 1, 1987, subsequently changed its name to Medicis Corporation and was merged with and into Medicis Corporation, which was incorporated in July 29, 1988 under the laws of Delaware, pursuant to an Agreement of Merger dated July 29, 1988. Medicis Corporation subsequently changed its name to Medicis Pharmaceutical Corporation.
	Medicis Pharmaceutical Corporation (“Medicis” or the “Company”) is the leading independent pharmaceutical company in the United States focusing primarily on the treatment of dermatological conditions. The Company offers prescription products and an over-the-counter (“OTC”) product emphasizing the clinical effectiveness, quality, affordability and cosmetic elegance of its products. Medicis has achieved a leading position in branded prescription products for the treatment of acne, acne-related conditions, dyschromias and hyperpigmentation disorders and also offers the leading OTC fade cream product in the United States. The Company has built its business by successfully introducing prescription products such as DYNACIN® and TRIAZ® for the treatment of acne, LUSTRA®, for the treatment of skin dyschromias and photoaging, as well as by marketing ESOTERICA®, an OTC fade cream product line. In addition, Medicis has acquired the dermatological products LOPROX®, TOPICORT® and A/T/S® from Hoechst Marion Roussel, Inc. In December 1999, Aventis S.A. (“Aventis”) was formed through the merger of Hoechst Marion Roussel A.G. of Germany and Rhone-Poulenc S.A. of France. Medicis’ continuing obligation under the product acquisition is with Aventis. Medicis also acquired LIDEX® and SYNALAR® corticosteroid product lines from Syntex USA, Inc. (“Syntex”). The Company derives a majority of its revenues from sales of the DYNACIN® products, as well as TRIAZ®, LOPROX® and LUSTRA® products (together with DYNACIN®, the “Key Products”).
	The Company derives a majority of its revenue from sales of the Key Products. The Company believes that sales of the Key Products will constitute the majority of net revenues for the foreseeable future. Accordingly, any factor adversely affecting the sale of the Key Products, individually or collectively, could have a material adverse effect on the Company’s business, financial condition and results of operations. Each of the Key Products could be rendered obsolete or uneconomical by regulatory or competitive changes. The sale of the Key Products could also be adversely affected by other factors,

11

Table of Contents

	including manufacturing or supply interruptions; the development of new competitive pharmaceuticals to treat the conditions addressed by the Key Products; the introduction of generic “non-branded” pharmaceutical products which claim to offer equivalent therapeutic benefits to conditions addressed by the Key Products; technological advances; factors affecting the cost of production; marketing or pricing actions by one or more of the Company’s competitors; changes in the prescribing practices of physicians; changes in the reimbursement policies of third-party payors; product liability claims; the outcome of disputes relating to trademarks, patents and other rights or other factors.
	The Company’s results of operations may vary from period to period due to a variety of factors including expenditures incurred to acquire, license and promote pharmaceuticals; expenditures and timing relating to divestures, acquisitions and integration of businesses; the introduction of new products by the Company or its competitors; cost increases from third-party manufacturers; manufacturing and supply interruptions; the availability and cost of raw materials; the mix of products sold by the Company; changes in marketing and sales expenditures; market acceptance of the Company’s products; competitive pricing pressures; the outcome of disputes relating to trademarks, patents and other rights; general economic and industry conditions that affect customer demand; and the Company’s level of research and development activities. In addition, the Company’s business has historically been subject to seasonal fluctuations, with lower sales generally being experienced in the first quarter of each fiscal year. As a result of customer buying patterns, a substantial portion of the Company’s revenues has been in the last month of each quarter. The Company schedules its inventory purchases to meet anticipated customer demand. As a result, relatively small delays in the receipt of manufactured products by the Company could result in revenues being deferred or lost. The Company’s operating expenses are based upon anticipated sales levels, and a high percentage of the Company’s operating expenses are relatively fixed in the short term. Consequently, variations in the timing of revenue recognition could cause significant fluctuations in operating results from period to period and may result in unanticipated periodic earnings shortfalls or losses. There can be no assurance that the Company will maintain or increase revenues or profitability or avoid losses in any future period.
	The Company recognizes revenues from sales upon shipment to its customers. At the time of sale, the Company records reserves for returns based upon estimates using historical experience. Sales are reported net of actual and estimated product returns and net of pricing adjustments and/or discounts. The Company applies royalty obligations to the cost of sales in the period the corresponding sales are recognized.
	Medicis’ customers include the nation’s leading wholesale pharmaceutical distributors, such as McKesson HBOC, Inc. (“McKesson”), Bergen Brunswig Corporation (“Bergen Brunswig”), Cardinal Health, Inc. (“Cardinal”), Bindley Western Industries, Inc. (“Bindley”) and other major drug chains. During fiscal 1999, McKesson and Cardinal accounted for 18.0% and 14.1%, respectively, of the Company’s sales. During fiscal 1998, McKesson, Bergen Brunswig and Cardinal accounted for 16.9%, 13.2% and 12.6%, respectively, of the Company’s sales. During fiscal 1997, McKesson, Cardinal and Bergen Brunswig accounted for 20.6%, 16.3% and 10.9%, respectively, of the

12

Table of Contents

	Company’s sales. The loss of any of these customers’ accounts could have a material adverse effect upon the Company’s business, financial condition or results of operations.
	The Company plans to spend substantial amounts of capital to continue the acquisition of and the research and development of pharmaceutical products. Actual expenditures will depend upon the Company’s financial condition, as well as the results of clinical testing, delays or changes in government-required testing and approval procedures, technological and competitive developments and strategic marketing decisions. The Company may increase total expenditures for research and development and expects that research and development expenditures as a percentage of net revenues will fluctuate from period to period. The Company can give no assurance that the research and development projects will provide technologies or products that will be patentable, commercially feasible or acceptable to government agencies whose approval may be necessary.
	The Company intends to seek additional acquisitions of products or companies to leverage its existing distribution channels and marketing infrastructure, to provide additional opportunities for growth, and to aggressively market formulations of existing products. The Company is also seeking licensing opportunities. The success of the Company’s efforts is subject to a number of risks and uncertainties including: dependence on sales of Key Products; integration of new product acquisitions; reliance upon third-party manufacturers to produce certain Key Products; the ability to effectively manage a changing business; uncertainties related to pharmaceutical pricing and reimbursement; the uncertainty of competitive forces within the pharmaceutical industry that affect both the market for its products and the availability of product lines for acquisitions that meet the Company’s acquisition or licensing criteria. The future results of operations, both annually and from quarter to quarter, are subject to a variety of factors applicable to the Company and to the industries and markets in which it operates.
	To enable Medicis to focus on its core marketing and sales activities, the Company selectively out-sources certain non-sales and non-marketing functions, such as laboratory research, manufacturing and warehousing. As the Company expands its activities in these areas, additional financial resources are expected to be utilized. The Company typically does not enter into long-term manufacturing contracts with third-party manufacturers. Whether or not such contracts exist, there can be no assurance that the Company will be able to obtain adequate supplies of such products in a timely fashion, on acceptable terms, or at all.

13

Table of Contents

      Results of Operations

	The following table sets forth certain data, as a percentage of net revenues for the periods indicated.

	Three Months Ended March 31, 2000 Compared to the Three Months Ended March 31, 1999

      Net Revenues

Net revenues for the three months ended March 31, 2000 (the “third quarter of fiscal 2000”) increased 16.1%, or $4.9 million, to $35.0 million from $30.2 million for the three months ended March 31, 1999 (the “third quarter of fiscal 1999”). The Company’s net revenue increased in the third quarter of fiscal 2000 primarily as a result of the continued growth of the DYNACIN®, LOPROX®, TRIAZ® and LUSTRA® products and the addition of BUPHENYL™, the Ucyclyd Pharma Inc. product line. The Company acquired the LOPROX® product line in November 1998 and the BUPHENYL™ products in April 1999. In fiscal 1999, the Company divested and licensed 16 non-strategic products to Bioglan Pharma, plc (“Bioglan”). Net revenue associated with those non-strategic products in the third quarter of fiscal 1999 was $4.2 million.

      Gross Profit

Gross profit during the third quarter of fiscal 2000 increased 14.2%, or $3.6 million, to $28.7 million from $25.2 million in the third quarter of fiscal 1999. As a percentage of net revenue, gross profit decreased to 82.0% in the third quarter of fiscal 2000 from 83.4% in the third quarter of fiscal 1999. This decrease was primarily due to increased sales of the Company’s DYNACIN® products which have a lower gross profit due to escalating royalties which are included in cost of goods sold.

14

Table of Contents

      Selling, General and Administrative Expenses

	Selling, general and administrative expenses in the third quarter of fiscal 2000 increased 19.8%, or $1.9 million, to $11.3 million from $9.5 million in the third quarter of fiscal 1999, primarily due to expenses related to an increase in variable costs commensurate with increased sales volume, and personnel costs associated with the hiring of additional full-time equivalent employees, primarily performing sales and marketing functions, and cost-of-living salary adjustments.
	Selling, general and administrative costs, as a percentage of net revenue, increased approximately 1.0 percentage point in the third quarter of fiscal 2000 relative to the third quarter of fiscal 1999, primarily due to an increase in personnel costs associated with the hiring of additional full-time equivalent employees, primarily performing sales and marketing functions.

      Research and Development Expenses

	Research and development expenses in the third quarter of fiscal 2000 increased 14.8%, or $0.1 million, to $0.8 million from $0.7 million in the third quarter of fiscal 1999, primarily due to expenses associated with the clinical support of the Company’s existing products.

      Depreciation and Amortization Expenses

	Depreciation and amortization expenses in the third quarter of fiscal 2000 increased 23.1%, or $0.4 million, to $1.9 million from $1.6 million in the second quarter of fiscal 1999, primarily due to amortization of the intangible assets associated with the Company’s acquisition of the BUPHENYL™ and VECTRIN® products.

      Operating Income

	Operating income during the third quarter of fiscal 2000 increased 9.2%, or $1.2 million, to $14.6 million from $13.4 million in the third quarter of fiscal 1999. This increase was primarily a result of higher sales volumes and consistent operating expenses as a percentage of net revenues from the third quarter of fiscal 2000 compared to the third quarter of fiscal 1999.

      Interest Income (Expense)

	Interest income in the third quarter of fiscal 2000 increased 21.7% or $0.6 million, to $3.4 million from $2.8 million in the third quarter of fiscal 1999 primarily due to higher cash, cash equivalent and short-term investment balances in the third quarter of fiscal 2000. The increased balances are primarily the result of the Company’s cash flows from operations and proceeds from the divestiture of the Company’s non-strategic products, offset by the $22.0 million paid in November 1999 to Aventis and the payments made in association with the acquisition of the BUPHENYL™ and VECTRIN® products.
	Interest expense in the third quarter of fiscal 2000 decreased 38.5% or $280,000, to $446,000 from $726,000 in the third quarter of fiscal 1999, primarily due to a decrease in imputed interest of $274,000. This decrease is a direct result of the $22.0 million paid in

15

Table of Contents

	November 1999 to Aventis, which reduced the contract obligation recorded in connection with the acquisition of the LOPROX®, TOPICORT® and A/T/S® products.

      Income Tax Expense

Income tax expense during the third quarter of fiscal 2000 decreased 24.5% or $2.1 million, to $6.5 million, from $8.6 million in the third quarter of fiscal 1999. The provision for income taxes recorded for the third quarter of fiscal 2000 reflects management’s estimate of the effective tax rate. This estimate is reevaluated by management each quarter based upon forecasts of income before taxes for the year. The decrease in income tax expense in the third quarter of fiscal 2000, as compared to the third quarter of fiscal 1999, is due to a decrease in pre-tax income. The decrease in pre-tax income is primarily due to a $7.1 million gain recognized on the sale of nine products to Bioglan in the third quarter of fiscal 1999 offset by increased sales volume in the third quarter of fiscal 2000.

      Gain on Sale of Intangible Assets

In the third quarter of fiscal 1999 the Company recognized a gain of $7.1 million, $4.3 million net of tax, on the sale of nine products to Bioglan for $10.9 million in cash and certain technologies that may further enhance the Company’s research and development pipeline. The products included in the sale were: A-FIL®, AFIRM®, BENZASHAVE®, BETA-LIFTx®, METED®, PRAMEGEL®, PACKER’S TAR SOAP®, THERAMYCIN Z® and TEXACORT®.

      Net Income

Net income during the third quarter of fiscal 2000 decreased approximately 20.8%, or $2.9 million, to $11.1 million from $14.0 million from the third quarter of fiscal 1999. The decrease is a result of the gain of $7.1 million, $4.3 million net of tax, on the sale of nine products to Bioglan in the third quarter of 1999. Absent the tax-effected gain on the sale of assets in fiscal 1999, net income increased approximately 14.1%, or $1.4 million, to $11.1 million from $9.7 million in the third quarter of fiscal 2000, compared to the third quarter of fiscal 1999. Net income in the 3rd quarter of fiscal 1999 includes net income from the divested brands. The increase is primarily attributable to an increase in sales volumes and higher interest income balances due to higher cash balances.

16

Table of Contents

	Nine Months Ended March 31, 2000 Compared to the Nine Months Ended March 31, 1999

      Net Revenues

Net revenues for the nine months ended March 31, 2000 (the “2000 nine months”) increased 20.6%, or $17.1 million, to $100.1 million from $83.0 million for the nine months ended March 31, 1999 (the “1999 nine months”) primarily as a result of revenue growth associated with the DYNACIN®, TRIAZ® and OVIDE® products. The increase also relates to a full nine months of revenue associated with LOPROX®, TOPICORT® and A/T/S® which were acquired in November 1998 and BUPHENYL™ which was acquired in April 1999. In fiscal 1999, the Company divested and licensed 16 non-strategic products to Bioglan. Net revenue associated with these products for the 1999 nine months was $17.6 million.

      Gross Profit

Gross profit in the 2000 nine months increased 20.0%, or $13.6 million, to $81.5 million from $67.9 million in the 1999 nine months. As a percentage of net revenue, gross profit decreased 0.4 percentage points to 81.5% in the 2000 nine months from 81.9% in the 1999 nine months. Gross profit remained consistent primarily as a result of revenue associated with LOPROX®, LUSTRA®, LIDEX® and BUPHENYL™, which enjoy higher gross profit percentages than the Company’s other products, as well as the divesture and license of 16 non-strategic products in fiscal 1999, which consisted primarily of products which had a lower gross profit percentage than the Company’s other products.

      Selling, General and Administrative Expenses

	Selling, general and administrative expenses in the 2000 nine months increased 15.5%, or $4.2 million, to $31.4 million from $27.2 million in the 1999 nine months. The increase is primarily due to an increase in selling, general and administrative expenses related to personnel costs associated with the hiring of additional full-time equivalent employees, primarily performing sales and marketing functions, and cost-of-living salary adjustments.
	Selling, general and administrative costs, as a percentage of net revenues, decreased 1.4 percentage points in the 2000 nine months compared to the 1999 nine months primarily due to the divesture and license of 16 non-strategic products which had higher selling, general and administrative costs as a percentage of net revenue than the Company’s prescription products.

      Research and Development Expenses

	Research and development expenses in the 2000 nine months increased 79.5%, or $1.5 million, to approximately $3.4 million, from $1.9 million in the 1999 nine months primarily due to the timing of various research and development projects and expenses associated with the clinical support of the Company’s existing products.

17

Table of Contents

      Depreciation and Amortization Expenses

	Depreciation and amortization expenses in the 2000 nine months increased 41.1%, or $1.6 million, to $5.5 million from $3.9 million in the 1999 nine months primarily due to amortization of the intangible assets associated with the Company’s acquisition of the LOPROX®, TOPICORT® and A/T/S® products in November 1998, the BUPHENYL™ products in April 1999 and the VECTRIN® products in September 1999.

      In-Process Research and Development

	The Company recorded a $9.5 million charge to operations as in-process research and development during the 1999 nine months as part of the allocated purchase price of the acquisition from Aventis. The amounts allocated to in-process research and development were based upon independent appraisals.

      Operating Income

Operating income in the 2000 nine months increased $15.8 million, to $41.2 million from $25.4 million in the 1999 nine months primarily as a result of the $9.5 million charge to operations for in-process research and development as part of the allocated purchase price of the acquisition from Aventis. Absent special charges, operating income in the 2000 nine months increased 17.9%, or $6.3 million, to $41.2 from $34.9 million in the 1999 nine months as a result of higher sales volume.

      Interest Income (Expense)

	Interest income in the 2000 nine months increased 14.7%, or $1.3 million to $10.0 million from approximately $8.7 million in the 1999 nine months, primarily due to higher cash, cash-equivalent and short-term investment balances in the 2000 nine months which were generated from cash flows from operations and proceeds from the divesture of non-strategic products in fiscal 1999, offset by the $22.0 million paid in November 1999 to Aventis and the payments made in association with the acquisition of the BUPHENYL™ and VECTRIN® products.
	Interest expense in the 2000 nine months increased 60.6%, or $0.7 million to $1.8 million from $1.1 million in the 1999 nine months, primarily as a result of an increase in imputed interest of $0.7 million related to the contract obligation recorded in connection with the acquisition of the LOPROX®, TOPICORT® and A/T/S® products.

      Income Tax Expense

Income tax expense in the 2000 nine months increased 22.1%, or $3.3 million, to $18.3 million from $15.0 million in the 1999 nine months. The provision for income taxes recorded for the 2000 nine months reflects management’s estimate of the effective tax rate expected to be applicable for the full fiscal year. This estimate is reevaluated by management each quarter based upon forecasts of income before taxes for the year. The increase in income tax expense in the 2000 nine months, as compared to the 1999 nine months, is due to an increase in pre-tax income. The increase in pre-tax income is primarily

18

Table of Contents

	due to the increased sales volumes in the 2000 nine months offset by selling, general and administrative expenses.

      Gain on Sale of Intangible Assets

In the third quarter of fiscal 1999 the Company recognized a gain of $7.1 million, $4.3 million net of tax, on the sale of nine products to Bioglan for $10.85 million in cash and certain technologies that may further enhance the Company’s research and development pipeline. The products included in the sale were: A-FIL®, AFIRM®, BENZASHAVE®, BETA-LIFTx®, METED®, PRAMEGEL®, PACKER’S TAR SOAP®, THERAMYCIN Z® and TEXACORT®.

      Net Income

Net income in the 2000 nine months increased approximately 23.5%, or $5.9 million to $31.2 million from $25.3 million in the 1999 nine months. This increase is primarily a result of increased sales volumes in the 2000 nine months offset by selling, general and administrative expenses. Net income in the 1999 nine months includes net income from the divested brands. Absent tax-effected special charges, net income in the 2000 nine months increased 16.5%, or $4.4 million, to $31.2 million from $26.8 million in the 1999 nine months as a result of an increase in sales volume and an increase in net interest income.

      Liquidity and Capital Resources

	Net cash provided by operating activities for the 2000 nine months increased $1.0 million to $27.2 million from $26.2 million in the 1999 nine months. The increase was primarily attributable to an increase in net income offset by changes in operating assets and liabilities.
	Net cash used in investing activities for the 2000 nine months decreased $62.9 million, to $2.2 million, from $65.1 million in the 1999 nine months. The change is primarily due to the $39.1 million in proceeds received from the sale of product rights to Bioglan and the fluctuation of the available-for-sale investments.
	Net cash provided by financing activities increased $3.7 million, to $7.4 million, from $3.7 million. This change in financing activities primarily relates to a change in stock option proceeds.
	In accordance with various manufacturing agreements, the Company is required to provide manufacturers with pro forma estimated production requirements by product and in accordance with minimum production runs. From time to time, the Company may not take possession of all merchandise which has been produced by the manufacturer. However, the Company records its obligation to the manufacturer at the time the finished goods inventory is completed.
	Inflation did not have a significant impact on the results of the Company during the 2000 nine months.

19

Table of Contents

      Part II. Other Information

      Item 6. Exhibits and Reports on Form 8-K

      (a) Exhibits

      No. 27.1 Financial Data Schedule

	(See Note 5 to the Notes to the Condensed Consolidated Financial Statements incorporated herein for computation of per common share results.)
	(b) No reports on Form 8-K were filed during the quarter for which this report is filed.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

20